Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 17, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients with suspected pneumocystis
- • with an indication for bronchial fibroscopy for BAL or induced sputum
- • no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition
- Exclusion Criteria:
- • Pneumocystis treated for more than 72 hours
- • pregnancy/breast-feeding
- • adult patients deprived of liberty, protected
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
